GSK plc · LSE:GSK

GSK — Algorithms for Hope 2021

16 slides from GSK's conference presentation, Jun 15, 2021

  1. Slide 1: Using AI to develop Medicines with a higher probability of success

    Algorithms for Hope, 15th June 2021 Using AI to develop Medicines with a higher probability of success Dr Patrick Schwab, GSK Artificial Intelligence and Machine Learning

  2. Slide 2: Introduction

    Introduction Hanafi, age 52 Chronic obstructive pulmonary disease (COPD) - Chronic inflammatory lung disease (difficulty breathing, cough, mucus) - Treated once-daily with triple therapy (inhaled glucosteroid, long-acting beta2-agonist, long-acting muscarinic agonist) - 15 and 25% reduction in moder

  3. Slide 3: How can we leverage AI and ML to get more breakthrough medicines to patients faster?

    How can we leverage artificial intelligence (AI) and machine learning (ML) to get more breakthrough medicines to patients faster?

  4. Slide 4: Drug Development Process

    Drug Development Process Discovery Preclinical Phase I Phase II Phase III Probability 60% 50% 30% 60% of success approved 1 medicine 10+ years Cook, David, et al. "Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework." Nature reviews Drug discovery 13.6 (2014):

  5. Slide 5: Eroom's law: Exponential drop in R&D productivity

    “Eroom’s law”: Exponential drop in R&D productivity Number of New Molecular Entities (NMEs) Probability of success for a per billion US$ R&D spending new medicine is roughly 5.5%. A single NME on average requires 100s of millions US$ R&D spending. This trend was, for decades, exponentially worsening

  6. Slide 6: Tools Enabling AI in Medicine Development

    Tools Enabling AI in Medicine Development CRISPR cell systems Multi-omics interventions 1 Functional Genomics deep learning lab automation 2 Machine Learning and Automation hardware 3 Large-scale Computation 6

  7. Slide 7: Human Genetics – A rich Tool for Medicine Development

    Human Genetics – A rich Tool for Medicine Development Causal understanding of the underlying mechanism of disease Higher probability of approval (EU/US) Targets (gene products) with high-quality human genetic evidence are up to three times more likely to succeed in the clinic. Population-scale Bioba

  8. Slide 8: How can we create a map of cellular causal mechanisms?

    Given the compelling evidence that a causal understanding of a medicine significantly increases probability of success, how can we create a map of cellular causal mechanisms?

  9. Slide 9: Decoding the Language of the Cell with High Content Imaging

    Decoding the Language of the Cell with High Content Imaging culture cells treated control (retinoic acid) apply perturbation untreated (CRISPR, control Molecule, …) cardiomyocytes (heart muscle cells) High content imaging with immunofluorescent staining of specific antigens enables us to understand

  10. Slide 10: Robotic Lab Automation

    Robotic Lab Automation Advances in robotic automation technology enable running thousands of petri dish (in-vitro) Experiments per day – generating experimental evidence at scale. Robots … • physically move 384 well plates, • apply perturbations, and • measure relevant cell parameters (e.g., imaging

  11. Slide 11: Using AI to Create a Map of Cellular Phenotypes

    Using AI to Create a Map of Cellular Phenotypes unhealthy Small healthy Molecule 1 Deep Learning Large Datasets Small Molecule 2 healthy CRISPR-KO UMAP2 Gene X unhealthy UMAP1 What perturbations move the molecular phenotype towards the healthy state? Effective perturbations could be attractive treat

  12. Slide 12: Uncovering Biological Causal Networks

    Uncovering Biological Causal Networks Human Genetics Studies (Genome-wide Association Studies) Gene X Disease Y Causal Evidence Scientific Literature Deep Learning single cell RNA sequencing (scRNAseq) Natural Language Processing 2 ML and Automation Representation Learning 12

  13. Slide 13: Experimental Feedback Loops

    Experimental Feedback Loops Experimental Design Generate Hypotheses Run Experiments “Gene X contributes to disease Y” Causal Experimental Maps Data Build Machine Learning Models 3 Large-scale Computation 13

  14. Slide 14: Continuous Improvement to Create a Map of Health and Disease

    Continuous Improvement to Create a Map Health and Disease biological understanding high-accuracy model With every experimental iteration, we ask new questions, get new answers and generate a rich and high-resolution understanding of the underlying disease biology. time 14 initial understanding

  15. Slide 15: Conclusion

    Conclusion With more than 8’000 potential treatments in preclinical development across the pharmaceutical and biotechnology R&D pipeline size industry1, an increase of the probability of success by just one percent would lead to the discovery of 80 potentially life- changing medicines for patients –

  16. Slide 16: Thank you!

    Thank you! Patrick Schwab patrick.x.schwab@gsk.com GlaxoSmithKline plc

GSK — Algorithms for Hope 2021 on 6ix